The groundbreaking therapy of tirzepatide peptide represents a exciting breakthrough in the care of type 2 diabetes. Different to existing drugs, tirzepatide affects multiple pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – resulting in greater b